We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.
- Authors
Siciliano, Valentina; Sangiorgi, Flavio; Del Vecchio, Pierluigi; Vahedi, Layla; Gross, Maya Manuela; Saviano, Angela; Ojetti, Veronica
- Abstract
Long-acting lipoglycopeptides (LGPs), such as dalbavancin and oritavancin, are semisynthetic antibiotics known for their strong effectiveness against a wide array of Gram-positive bacteria. This includes Staphylococcus aureus, both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, coagulase-negative Staphylococci (CoNS), streptococci, and vancomycin-sensitive Enterococcus faecalis. A literature search was conducted on PubMed and on ClinicalTrials.gov to identify articles published until July 2023 investigating the use of oritavancin and dalbavancin in clinical practice. The review included case reports, case series, observational studies, and clinical studies. Although more consistent data are needed, LGPs seem to be a good alternative that may provide a quicker hospital discharge and reduce long-term intravenous access and therapy. This is attributed to their unique pharmacologic and pharmacokinetic characteristics. More quality data (i.e., number of patients treated with clinical success) are needed before clinicians may use these therapies more widely.
- Subjects
GRAM-positive bacteria; STAPHYLOCOCCUS aureus; METHICILLIN-resistant staphylococcus aureus; INTRAVENOUS therapy; ENTEROCOCCUS faecalis; STAPHYLOCOCCUS
- Publication
Pathogens, 2024, Vol 13, Issue 3, p189
- ISSN
2076-0817
- Publication type
Case Study
- DOI
10.3390/pathogens13030189